SC 13G 1 l113g.htm SCHEDULE 13G

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

ENDRA Life Sciences Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

29273B302

(CUSIP Number)

June 4, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 29273B302

13G

Page 2 of 5 Pages

1	NAME OF REPORTING PERSONS

	L1 Capital Global Opportunities Master Fund, Ltd.
2	CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP
	(a) ☐
	(b) ☐
3	SEC USE ONLY


4	CITIZENSHIP OR PLACE OF ORGANIZATION

	Cayman Islands
		5	SOLE VOTING POWER

			7,921,648 (1)(2)
NUMBER OF		6	SHARED VOTING POWER
SHARES
BENEFICIALLY			0
OWNED BY		7	SOLE DISPOSITIVE POWER
EACH REPORTING
PERSON WITH			7,921,648 (1)(2)
		8	SHARED DISPOSITIVE POWER

			0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	7,921,648 (1)(2)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

	9.99% (1)(2)
12	TYPE OF REPORTING PERSON
	FI (3)

(1)

Represents 1,200,000 shares of the Issuer’s Common Stock purchased by the Reporting Person and, due to a 9.99% beneficial ownership limitation, 6,721,648 shares of Common Stock issuable upon the exercise of pre-funded warrants exercisable within 60 days. Does not include 4,364,506 shares of Common Stock issuable upon the exercise of pre-funded warrants, which are subject to a 9.99% beneficial ownership limitation. Also does not include 12,286,154 Series A Warrants and 12,286,154 Series B Warrants, both of which are subject to 9.99% beneficial ownership limitation. The numbers in this Schedule 13G do not give effect to the increased numbers of shares potentially issuable under the Series A Warrants and Series B Warrants because the meeting to obtain the stockholder approval of the Series A Warrants and B Warrants and the Charter Amendment to increase the authorized shares of the Issuer’s common stock is not likely to occur within 60 days of June 4, 2024, and the beneficial ownership limitations will apply in any event.

(2)

Based on 72,574,120 shares of Common Stock outstanding upon the closing of an offering as reported in the Issuer’s Prospectus dated June 4, 2024.

(3)

The Reporting Person has not acquired the securities with any purpose, or with the effect, of changing or influencing the control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect, including any transaction subject to Rule 13d-3(b).

CUSIP No. 29273B302

13G

Page 3 of 5 Pages

Item 1.

(a)

Name of Issuer:

ENDRA Life Sciences Inc.

(b)

Address of Issuer’s Principal Executive Offices:

3600 Green Court, Suite 350

Ann Arbor, MI 48105

Item 2.

(a)	Name of Person Filing:

	L1 Capital Global Opportunities Master Fund, Ltd.

(b)	Address of Principal Business Office or, if none, Residence:

	161A Shedden Road, 1 Artillery Court PO Box 10085 Grand Cayman, Cayman Islands KY1-1001

(c)	Citizenship:

	Cayman Islands

(d)	Title of Class of Securities:

	Common Stock, par value $0.0001 per share

(e)	CUSIP Number:

	29273B302

Item 3.

Not applicable.


CUSIP No. 29273B302		13G		Page 4 of 5 Pages

Item 4. Ownership.

(a)–(c)

The information required by Items 4(a)-(c) is set forth in Rows (5)-(9) and Row (11) of the cover page and is incorporated herein by reference.

The percentage set forth on Row (11) of the cover page for the reporting person is based on 72,574,120 shares of Common Stock outstanding upon the closing of an offering based on the Issuer’s Prospectus dated June 4, 2024.

David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer’s securities described herein. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 29273B302

13G

Page 5 of 5 Pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.


	By:	L1 Capital Global Opportunities Master Fund, Ltd.

June 14, 2024	By:	/s/ David Feldman
		David Feldman, Director

SEC Form SC 13G filed by ENDRA Life Sciences Inc.